Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 21, 2012; 18(31): 4118-4126
Published online Aug 21, 2012. doi: 10.3748/wjg.v18.i31.4118
Published online Aug 21, 2012. doi: 10.3748/wjg.v18.i31.4118
Table 1 Background of patients with liver disorders
Chronic hepatitis C | NAFLD | Autoimmune liver disease | |
Number | 40 | 15 | 3 |
Gender (M/F) | 25/15 | 14/1 | 1/2 |
Age (yr) | 64.4 ± 11.3 | 52.5 ± 13.7 | 65.7 ± 4.0 |
HCV viral load(10n/mL) | 6.2 ± 0.8 | ||
≥ 5log/< 5log/ND | 35/3/2 | ||
WBC count (/μL) | 4153 ± 994 | 6800 ± 1578 | 3967 ± 723 |
RBC count (104/μL) | 415 ± 59 | 490 ± 51 | 448 ± 48 |
Hemoglobin (g/dL) | 13.1 ± 1.8 | 15.5 ± 1.1 | 12.5 ± 1.7 |
Platelet count (104/μL) | 13.8 ± 5.7 | 20.3 ± 8.4 | 17.2 ± 5.1 |
AST (IU/L) | 94.2 ± 55.5 | 84.5 ± 50.0 | 129.3 ± 90.5 |
ALT (IU/L) | 93.4 ± 51.1 | 131.9 ± 72.5 | 96.7 ± 50.1 |
γ-GTP (IU/L) | 72.9 ± 60.5 | 181.9 ± 197.5 | 120.3 ± 74.2 |
LDH (IU/L) | 237.8 ± 54.8 | 228.9 ± 44.4 | 270 ± 44.3 |
ALP (IU/L) | 318.1 ± 116.8 | 303.4 ± 106.8 | 391 ± 293.1 |
Total bilirubin (mg/dL) | 0.84 ± 0.29 | 0.8 ± 0.44 | 0.67 ± 0.15 |
Total cholesterol (mg/dL) | 162 ± 35.2 | 188.5 ± 49.1 | 174.7 ± 40.1 |
Total protein (g/dL) | 7.5 ± 0.6 | 7.7 ± 0.3 | 7.9 ± 0.9 |
Albumin (g/dL) | 3.9 ± 0.4 | 4.4 ± 0.3 | 3.9 ± 0.9 |
BUN (mg/dL) | 16.2 ± 4.0 | 13.6 ± 3.2 | 15.3 ± 3.1 |
Creatinine (mg/dL) | 0.76 ± 0.16 | 0.75 ± 0.1 | 0.62 ± 0.06 |
Table 2 Response rate of MK615 therapy in patients with liver disorder (%)
ALT | AST | |
Chronic hepatitis C | 20/40 (50) | 16/40 (40) |
NAFLD | 5/15 (33) | 6/15 (40) |
Autoimmune liver disease | 1/3 (33) | 3/3 (100) |
Total | 26/58 (45) | 25/58 (43) |
Table 3 Changes of serum level during MK615 therapy in patients with liver disorders
Before therapy | During therapy 12 wk | P value1 | |
WBC count (/μL) | 4828 ± 1640 | 4977 ± 1855 | NS |
RBC count (104/μL) | 436 ± 65 | 435 ± 65 | NS |
Hemoglobin (g/dL) | 13.7 ± 2.0 | 13.8 ± 1.9 | NS |
Platelet count (104/μL) | 15.7 ± 7.0 | 15.6 ± 6.6 | NS |
AST (IU/L) | 94 ± 56 | 66 ± 35 | < 0.05 |
ALT (IU/L) | 104 ± 59 | 72 ± 39 | < 0.05 |
γ-GTP (IU/L) | 104 ± 121 | 74 ± 93 | < 0.05 |
LDH (IU/L) | 237 ± 52 | 227 ± 52 | < 0.05 |
ALP (IU/L) | 318 ± 124 | 298 ± 126 | < 0.05 |
Total bilirubin (mg/dL) | 0.8 ± 0.3 | 0.8 ± 0.3 | NS |
Total cholesterol (mg/dL) | 170 ± 40 | 171 ± 43 | NS |
Total protein (g/dL) | 7.6 ± 0.6 | 7.6 ± 0.5 | NS |
Albumin (g/dL) | 4.0 ± 0.5 | 4.1 ± 0.4 | NS |
BUN (mg/dL) | 15.5 ± 3.9 | 14.7 ± 3.5 | NS |
Creatinine (mg/dL) | 0.75 ± 0.15 | 0.74 ± 0.15 | NS |
- Citation: Hokari A, Ishikawa T, Tajiri H, Matsuda T, Ishii O, Matsumoto N, Okuse C, Takahashi H, Kurihara T, Kawahara KI, Maruyama I, Zeniya M. Efficacy of MK615 for the treatment of patients with liver disorders. World J Gastroenterol 2012; 18(31): 4118-4126
- URL: https://www.wjgnet.com/1007-9327/full/v18/i31/4118.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i31.4118